Form 4 holding
Chief Medical Officer
GILEAD SCIENCES, INC.
- Security class
- Common Stock
- Shares / value
- 82,850
- Estimated value
- $7,650,369
- Report date
- 10 Dec 2024
- Price
- $92.34
- Ownership
- Direct
Merdad Parsey
Insider Reports History
- Reporting-owner location
- San Carlos, CA
- Latest reporting-owner signature
-
By: /s/ James Kastenmayer, Attorney-in-Fact for: Merdad Parsey
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Merdad Parsey
Form 4 holding
Chief Medical Officer
GILEAD SCIENCES, INC.
- Security class
- Restricted Stock Unit
- Shares / value
- 36,753
- Estimated value
- $3,393,772
- Report date
- 10 Dec 2024
- Price
- $92.34
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Chief Medical Officer
GILEAD SCIENCES, INC.
- Security class
- Restricted Stock Unit
- Shares / value
- 44,394
- Estimated value
- $2,896,709
- Report date
- 10 Jun 2024
- Price
- $65.25
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
ARDELYX, INC.
- Security class
- Common Stock
- Shares / value
- 83,746
- Estimated value
- $501,638
- Report date
- 16 Jun 2026
- Price
- $5.99
- Ownership
- Direct
Form 4 holding
Director
Sagimet Biosciences Inc.
- Security class
- Series A Common Stock
- Shares / value
- 12,794
- Estimated value
- $52,455
- Report date
- 18 Jul 2023
- Price
- $4.10
- Ownership
- Direct
Form 4 holding
Chief Medical Officer
GILEAD SCIENCES, INC.
- Security class
- Non-qualified Stock Option (Right to Buy)
- Shares / value
- 89,660
- Estimated value
- Report date
- 10 Mar 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Sagimet Biosciences Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 51,459
- Estimated value
- Report date
- 05 Jun 2024
- Price
- Ownership
- Direct
- Underlying class
- Series A Common Stock
- Underlying amount
Form 4 holding
Director
ARDELYX, INC.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 39,715
- Estimated value
- Report date
- 16 Jun 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
ArriVent BioPharma, Inc.
- Security class
- Stock Option (right to buy)
- Shares / value
- 28,346
- Estimated value
- Report date
- 28 Apr 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
ArriVent BioPharma, Inc.
- Security class
- Non-Qualified Stock Option (right to buy)
- Shares / value
- 13,562
- Estimated value
- Report date
- 18 Jun 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Chief Medical Officer
GILEAD SCIENCES, INC.
- Security class
- Non-qualified Stock Option (Right to Buy)
- Shares / value
- 196
- Estimated value
- Report date
- 27 Nov 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Sagimet Biosciences Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- Report date
- 18 Jul 2023
- Price
- Ownership
- Direct
Form 4 holding
Director
Sagimet Biosciences Inc.
- Security class
- Series E Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 18 Jul 2023
- Price
- Ownership
- Direct
- Underlying class
- Series A Common Stock
- Underlying amount
Insider Reports Filed by Merdad Parsey
4
AVBP
ArriVent BioPharma, Inc.
- Report period
- 18 Jun 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 22 Jun 2026, 21:51
- Role
- Director
- Next action
- Open filing details
4
ARDX
ARDELYX, INC.
- Report period
- 16 Jun 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 18 Jun 2026, 17:14
- Role
- Director
- Next action
- Open filing details
4
ARDX
ARDELYX, INC.
- Report period
- 18 Jun 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 23 Jun 2025, 20:41
- Role
- Director
- Next action
- Open filing details
4
AVBP
ArriVent BioPharma, Inc.
- Report period
- 18 Jun 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 20 Jun 2025, 19:33
- Role
- Director
- Next action
- Open filing details
4
ARDX
ARDELYX, INC.
- Report period
- 28 Apr 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 14 May 2025, 19:51
- Role
- Director
- Next action
- Open filing details
3
ARDX
ARDELYX, INC.
- Report period
- 28 Apr 2025
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 13 May 2025, 21:47
- Role
- Director
- Next action
- Open filing details
4
AVBP
ArriVent BioPharma, Inc.
- Report period
- 28 Apr 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 29 Apr 2025, 16:51
- Role
- Director
- Next action
- Open filing details
3
AVBP
ArriVent BioPharma, Inc.
- Report period
- 28 Apr 2025
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 29 Apr 2025, 16:49
- Role
- Director
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 10 Dec 2024
- Transactions
- 3
- Transaction value
- -$163,534
- Accepted by SEC
- 11 Dec 2024, 19:24
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 27 Nov 2024
- Transactions
- 9
- Transaction value
- -$6,014,325
- Accepted by SEC
- 29 Nov 2024, 20:10
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 06 Nov 2024
- Transactions
- 4
- Transaction value
- -$893,485
- Accepted by SEC
- 07 Nov 2024, 16:32
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 01 Oct 2024
- Transactions
- 1
- Transaction value
- -$167,660
- Accepted by SEC
- 02 Oct 2024, 16:58
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 12 Sep 2024
- Transactions
- 3
- Transaction value
- -$347,287
- Accepted by SEC
- 13 Sep 2024, 19:07
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 10 Sep 2024
- Transactions
- 3
- Transaction value
- -$143,823
- Accepted by SEC
- 11 Sep 2024, 19:33
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 01 Jul 2024
- Transactions
- 1
- Transaction value
- -$137,260
- Accepted by SEC
- 01 Jul 2024, 20:06
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 10 Jun 2024
- Transactions
- 3
- Transaction value
- -$113,796
- Accepted by SEC
- 11 Jun 2024, 19:15
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
SGMT
Sagimet Biosciences Inc.
- Report period
- 05 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 07 Jun 2024, 16:07
- Role
- Director
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 01 Apr 2024
- Transactions
- 1
- Transaction value
- -$145,920
- Accepted by SEC
- 02 Apr 2024, 18:38
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 10 Mar 2024
- Transactions
- 7
- Transaction value
- -$360,801
- Accepted by SEC
- 11 Mar 2024, 21:14
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 28 Feb 2024
- Transactions
- 2
- Transaction value
- -$744,984
- Accepted by SEC
- 29 Feb 2024, 18:35
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 31 Jan 2024
- Transactions
- 3
- Transaction value
- -$1,855,466
- Accepted by SEC
- 02 Feb 2024, 14:42
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 10 Dec 2023
- Transactions
- 3
- Transaction value
- -$100,276
- Accepted by SEC
- 11 Dec 2023, 19:10
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 12 Sep 2023
- Transactions
- 1
- Transaction value
- -$115,562
- Accepted by SEC
- 13 Sep 2023, 18:50
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 10 Sep 2023
- Transactions
- 3
- Transaction value
- -$97,128
- Accepted by SEC
- 11 Sep 2023, 20:19
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
SGMT
Sagimet Biosciences Inc.
- Report period
- 18 Jul 2023
- Transactions
- 14
- Transaction value
- $0
- Accepted by SEC
- 20 Jul 2023, 16:17
- Role
- Director
- Next action
- Open filing details
3
SGMT
Sagimet Biosciences Inc.
- Report period
- 13 Jul 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 13 Jul 2023, 21:05
- Role
- Director
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 13 Jun 2023
- Transactions
- 1
- Transaction value
- -$114,196
- Accepted by SEC
- 14 Jun 2023, 17:48
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 10 Jun 2023
- Transactions
- 3
- Transaction value
- -$101,087
- Accepted by SEC
- 12 Jun 2023, 16:45
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 13 Mar 2023
- Transactions
- 1
- Transaction value
- -$483,893
- Accepted by SEC
- 14 Mar 2023, 18:20
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 10 Mar 2023
- Transactions
- 7
- Transaction value
- -$423,576
- Accepted by SEC
- 13 Mar 2023, 21:09
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 01 Mar 2023
- Transactions
- 1
- Transaction value
- -$1,038,225
- Accepted by SEC
- 02 Mar 2023, 18:01
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 15 Feb 2023
- Transactions
- 1
- Transaction value
- +$21,199
- Accepted by SEC
- 23 Feb 2023, 15:16
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 24 Jan 2023
- Transactions
- 3
- Transaction value
- -$1,491,271
- Accepted by SEC
- 26 Jan 2023, 14:40
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 30 Dec 2022
- Transactions
- 1
- Transaction value
- -$47,187
- Accepted by SEC
- 03 Jan 2023, 19:05
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 10 Dec 2022
- Transactions
- 3
- Transaction value
- -$42,753
- Accepted by SEC
- 13 Dec 2022, 14:14
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 10 Nov 2022
- Transactions
- 3
- Transaction value
- -$187,337
- Accepted by SEC
- 14 Nov 2022, 11:42
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 10 Sep 2022
- Transactions
- 3
- Transaction value
- -$31,400
- Accepted by SEC
- 12 Sep 2022, 16:05
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 10 Jun 2022
- Transactions
- 3
- Transaction value
- -$29,459
- Accepted by SEC
- 13 Jun 2022, 19:53
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 10 Mar 2022
- Transactions
- 7
- Transaction value
- -$203,010
- Accepted by SEC
- 14 Mar 2022, 21:20
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES, INC.
- Report period
- 15 Feb 2022
- Transactions
- 1
- Transaction value
- +$18,141
- Accepted by SEC
- 13 Apr 2022, 20:32
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES INC
- Report period
- 26 Jan 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 28 Jan 2022, 19:51
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES INC
- Report period
- 10 Nov 2021
- Transactions
- 3
- Transaction value
- -$156,182
- Accepted by SEC
- 12 Nov 2021, 17:01
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
GILD
GILEAD SCIENCES INC
- Report period
- 15 Aug 2021
- Transactions
- 1
- Transaction value
- +$55.08
- Accepted by SEC
- 24 Aug 2021, 18:12
- Role
- Chief Medical Officer
- Next action
- Open filing details